After Laying Off Most of its Staff, AxCell Sees its Future in Virtual Drug Discovery | GenomeWeb

After failing to snag any revenue-generating collaborations with private-sector partners, AxCell Biosciences has scaled back its effort. Earlier this month the Newtown, Penn.-based provider of protein-protein interaction data laid off 14 of its 20 employees and resigned itself to pursuing drug discovery through its academic collaborators — what AxCell interim CEO Michael Becker refers to as a “virtual drug-discovery model.”

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.